Secondary Prevention of Hyperlipidemia After Coronary Artery Bypass Graft: From Acute Care to Primary Care
Authors:
- 1 September 2004
- journal article
- Published by AACN Publishing in American Journal of Critical Care
- Vol. 13 (5) , 411-415
Abstract
• Background Clinical trials have established that secondary prevention of hyperlipidemia in patients after coronary artery bypass graft (CABG) surgery prevents progression of atherosclerosis. A multidisciplinary team promotes secondary prevention by prescribing antihyperlipidemic agents, screening for risk factors, and providing education on disease, diet, and medications. Information is minimal on the number of patients who continue with antihyperlipidemic therapy or follow-up with a primary care provider for cholesterol management after antihyperlipidemic therapy is initiated in an acute surgical setting.• Objectives To determine (1) the frequency of use of antihyperlipidemic agents before CABG surgery, at hospital discharge, and approximately 9 months after discharge and (2) the occurrence of cholesterol monitoring by a primary care provider at least once between discharge and telephone follow-up.• Methods Observational study of 135 patients undergoing CABG surgery at a regional medical center during a 4-month period. Patients were contacted by telephone between 5 and 12 months after discharge and asked about continued use of antihyperlipidemic agents and cholesterol monitoring since discharge.• Results Before surgery, 56% of the patients were taking an antihyperlipidemic agent. At discharge, 95% were taking an antihyperlipidemic agent. At the time of study follow-up, 91% were still taking an antihyperlipidemic agent, and 84% had follow-up cholesterol monitoring by their primary care provider.• Conclusion Initiation of an antihyperlipidemic agent and provision of education during hospitalization for CABG surgery results in a high percentage of patients continuing antihyperlipidemic therapy and having cholesterol levels monitored by their primary care provider after discharge.Keywords
This publication has 9 references indexed in Scilit:
- Are we negating the benefits of CABG by forgetting secondary prevention?Journal of Human Hypertension, 2002
- Lipid-lowering therapy at hospital discharge after coronary artery bypass graftingAmerican Journal of Health-System Pharmacy, 2002
- Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)JAMA, 2001
- Ten year audit of secondary prevention in coronary bypass patientsBMJ, 2000
- Pravastatin prevents clinical events in revascularized patients with average cholesterol concentrationsJACC, 1999
- The Effect of Aggressive Lowering of Low-Density Lipoprotein Cholesterol Levels and Low-Dose Anticoagulation on Obstructive Changes in Saphenous-Vein Coronary-Artery Bypass GraftsNew England Journal of Medicine, 1997
- The Effect of Pravastatin on Coronary Events after Myocardial Infarction in Patients with Average Cholesterol LevelsNew England Journal of Medicine, 1996
- Inadequate management of hyperlipidaemia after coronary bypass surgery shown by medical audit.Heart, 1994
- Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)The Lancet, 1994